Category Archives: Cancer Stem Cell

Cancer Stem Cell News is an online publication and email newsletter that curates the top research publications and reviews about cancer progenitor cells and cancer stem cells.
Subscribe
Cancer Stem Cell News consolidates the most recent publications covering research areas such as the identification and isolation of cancer stem cells, their proliferation and differentiation characteristics, gene expression and regulatory pathways, and the development of anti-cancer therapies. We also include cancer stem cell jobs and events hosted by leading research organizations, societies, and institutes.

EVI1 Phosphorylation at S436 Regulates Interactions with CtBP1 and DNMT3A and Promotes Self-Renewal

Wild-type EVI1 with S436 available for phosphorylation, but not non-phosphorylatable EVI1-S436A, conferred hematopoietic progenitor cell self-renewal and was associated with significantly higher organized transcriptional patterns.
[Cell Death & Disease]
Paredes, R., Kelly, J. R., Geary, B., Almarzouq, B., Schneider, M., Pearson, S., Narayanan, P., Williamson, A., Lovell, S. C., Wiseman, D. H., Chadwick, J. A., Jones, N. J., Kustikova, O., Schambach, A., Garner, T., Amaral, F. M. R., Pierce, A., Stevens, A., Somervaille, T. C. P., … Meyer, S. (2020). EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal. Cell Death & Disease, 11(10), 1–14. https://doi.org/10.1038/s41419-020-03099-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Targeting Interleukin-17 Receptor B Enhances Gemcitabine Sensitivity through Downregulation of Mucins in Pancreatic Cancer

Investigators showed interlukine-17 receptor B (IL-17RB) expression was positively correlated with mucin 1 (MUC1) and MUC4 expression in pancreatic cancer cells and tumor tissue.
[Scientific Reports]
Tsai, L.-H., Hsu, K.-W., Chiang, C.-M., Yang, H.-J., Liu, Y.-H., Yang, S.-F., Peng, P.-H., Cheng, W.-C., & Wu, H.-H. (2020). Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. Scientific Reports, 10(1), 17817. https://doi.org/10.1038/s41598-020-73659-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

WNT11-FZD7-DAAM1 Signaling Supports Tumor Initiating Abilities and Melanoma Amoeboid Invasion

Investigators showed that WNT11-FZD7-DAAM1 activated Rho-ROCK1/2-Myosin II and played a crucial role in regulating tumour-initiating potential, local invasion and distant metastasis formation.
[Nature Communications]
Rodriguez-Hernandez, I., Maiques, O., Kohlhammer, L., Cantelli, G., Perdrix-Rosell, A., Monger, J., Fanshawe, B., Bridgeman, V. L., Karagiannis, S. N., Penin, R. M., Marcolval, J., Marti, R. M., Matias-Guiu, X., Fruhwirth, G. O., Orgaz, J. L., Malanchi, I., & Sanz-Moreno, V. (2020). WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nature Communications, 11(1), 5315. https://doi.org/10.1038/s41467-020-18951-2 Cite
Full ArticlePress Release
Bookmark

No account yet? Register

0
Share

Exploiting Oxidative Phosphorylation to Promote the Stem and Immunoevasive Properties of Pancreatic Cancer Stem Cells

Investigators describe a 2D in vitro system for long-term enrichment of pancreatic cancer stem cells (CSCs) that was amenable to biological and CSC-specific studies.
[Nature Communications]
Valle, S., Alcalá, S., Martin-Hijano, L., Cabezas-Sáinz, P., Navarro, D., Muñoz, E. R., Yuste, L., Tiwary, K., Walter, K., Ruiz-Cañas, L., Alonso-Nocelo, M., Rubiolo, J. A., González-Arnay, E., Heeschen, C., Garcia-Bermejo, L., Hermann, P. C., Sánchez, L., Sancho, P., Fernández-Moreno, M. Á., & Sainz, B. (2020). Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Nature Communications, 11(1), 5265. https://doi.org/10.1038/s41467-020-18954-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

Pharmacological Ascorbate Inhibits Pancreatic Cancer Metastases via a Peroxide-Mediated Mechanism

Several in vitro and in vivo mechanisms involved in pancreatic cancer (PDAC) metastases were investigated following treatment with P-AscH−. Serum from PDAC patients in clinical trials with P-AscH− were tested for the presence and quantity of circulating tumor cell-derived nucleases.
[Scientific Reports]
O’Leary, B. R., Alexander, M. S., Du, J., Moose, D. L., Henry, M. D., & Cullen, J. J. (2020). Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism. Scientific Reports, 10(1), 17649. https://doi.org/10.1038/s41598-020-74806-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Tenascin C Promotes Cancer Cell Plasticity in Mesenchymal Glioblastoma

Researchers identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma subtype with high NF-κB signaling activity. Silencing TNC decreased proliferation, migration and suppresses self-renewal of glioma stem cells.
[Oncogene]
Angel, I., Pilo Kerman, O., Rousso-Noori, L., & Friedmann-Morvinski, D. (2020). Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma. Oncogene, 1–15. https://doi.org/10.1038/s41388-020-01506-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

DYRK2 Controls a Key Regulatory Network in Chronic Myeloid Leukemia Stem Cells

Scientists discuss molecular maintenance in leukemia stem cells in chronic myeloid leukemia and provide a more in-depth discussion of the dual-specificity kinase DYRK2, which has been identified as a novel actionable checkpoint in a critical leukemic network.
[Experimental and Molecular Medicine]
Park, C. S., & Lacorazza, H. D. (2020). DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells. Experimental & Molecular Medicine, 1–10. https://doi.org/10.1038/s12276-020-00515-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Merck announced that the FDA has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Practical Classification of Triple-Negative Breast Cancer: Intratumoral Heterogeneity, Mechanisms of Drug Resistance, and Novel Therapies

Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across triple negative breast cancer subtypes, prompting the implementation of biomarker-driven therapeutic approaches.
[npj breast cancer]
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020). Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Npj Breast Cancer, 6(1), 1–16. https://doi.org/10.1038/s41523-020-00197-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Nanoparticle-Delivered Miriplatin Ultrasmall Dots Suppress Triple Negative Breast Cancer Lung Metastasis by Targeting Circulating Tumor Cells

Investigators found that active targeting nanoparticles displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing cancer stem cell-like property of triple negative breast cancer cells, compared to conventional cisplatin and miriplatin.
[Journal of Controlled Release]
Li, Y., Qian, D., Lin, H.-P., Xie, J., Yang, P., Maddy, D., Xiao, Y., Huang, X., Wang, Z., & Yang, C. (2020). Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2020.10.015 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

RASSF1A Inhibits PDGFB-Driven Malignant Phenotypes of Nasopharyngeal Carcinoma Cells in a YAP1-Dependent Manner

The authors observed that ras-association domain family protein1 isoform A (RASSF1A) expression inhibited the malignant phenotypes of nasopharyngeal carcinoma (NPC) cells. Stable silencing of RASSF1A in NPC cell lines induced self-renewal properties and tumorigenicity in vivo/in vitro and the acquisition of an invasive phenotype in vitro.
[Cell Death & Disease]
Liang, Y.-Y., Deng, X.-B., Lin, X.-T., Jiang, L.-L., Huang, X.-T., Mo, Z.-W., Yuan, Y.-W., & Teh, M.-T. (2020). RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner. Cell Death & Disease, 11(10), 1–12. https://doi.org/10.1038/s41419-020-03054-z Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share